ketoconazole has been researched along with Disease Models, Animal in 60 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Candida sepsis has become an increasing problem in ICU patients with up to 50 per cent mortality rate." | 5.28 | The use of ketoconazole in prophylaxis of Candida sepsis. ( Lloyd, L; Rietschel, P; VanEgmond, E, 1989) |
| "Pretreatment with ketoconazole for 48 hr completely abolished the protective effect of a subsequent therapy with amphotericin B, whether ketoconazole therapy was stopped (P less than ." | 5.27 | The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. ( Frick, PG; Schaffner, A, 1985) |
| "It has been difficult to experimentally reproduce synergistic effects of ketoconazole on terfenadine-induced torsade de pointes." | 3.96 | Utilization of the chronic atrioventricular block cynomolgus monkey as an in vivo model to evaluate drug interaction-associated torsade de pointes. ( Chiba, K; Goto, A; Hagiwara-Nagasawa, M; Izumi-Nakaseko, H; Kambayashi, R; Matsumoto, A; Nunoi, Y; Sakamoto, K; Sugiyama, A, 2020) |
| " Intrathecal administration of the P450c17 inhibitor, ketoconazole during the induction phase of neuropathic pain (day 0 to day 3 post-surgery) significantly reduced the development of mechanical allodynia and thermal hyperalgesia in the ipsilateral hind paw." | 3.91 | Spinal cytochrome P450c17 plays a key role in the development of neuropathic mechanical allodynia: Involvement of astrocyte sigma-1 receptors. ( Beitz, AJ; Choi, HS; Choi, SR; Han, HJ; Kang, SY; Lee, JH; Roh, DH; Yoon, SY, 2019) |
| "The aim of the present research work was to develop ketoconazole microemulsion-loaded hydrogel formulation containing nigella oil as permeation enhancer for the treatment of onychomycosis." | 3.91 | Formulation evaluation of ketoconazole microemulsion-loaded hydrogel with nigella oil as a penetration enhancer. ( Amra, K; Momin, M, 2019) |
| " Accordingly, this study investigates the effects of CYP3A4 inhibitor, ketoconazole (KTZ), on the antischistosomal potential of these quinolines against Schistosoma mansoni infection by evaluating parasitological, histopathological, and biochemical parameters." | 3.79 | Effect of ketoconazole, a cytochrome P450 inhibitor, on the efficacy of quinine and halofantrine against Schistosoma mansoni in mice. ( Abdel-Aal Sabra, AN; El-Lakkany, NM; Hammam, OA; Seif El-Din, SH, 2013) |
| "The triazole Bay R 3783 was compared with fluconazole, itraconazole, ketoconazole, and amphotericin B in rodent models of superficial and systemic candidiasis, meningocerebral cryptococcosis, and pulmonary aspergillosis." | 3.68 | Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis. ( Hector, RF; Yee, E, 1990) |
| "The therapy of coccidioidomycosis has been an early target, both experimentally and clinically, for study of new members of the azole class of drugs, because of the recognition that coccidioidomycosis is one of the most difficult mycoses to treat, and because our research group and our collaborators have been eager to pioneer new therapies for this problem pathogen." | 2.44 | Azole therapy of clinical and experimental coccidioidomycosis. ( Clemons, KV; Stevens, DA, 2007) |
| " The same results could not be achieved with the same concentration or dosage of either ketoconazole or fluconazole." | 2.38 | Oral and parenteral treatment with itraconazole in various superficial and systemic experimental fungal infections. Comparisons with other antifungals and combination therapy. ( Van Cutsem, J, 1990) |
| "Treatment with melatonin after Keto administration caused significant increases in FSH, LH, superoxide dismutase, total antioxidant capacity (TAC), sperm count, and sperm morphology but significant decreases in MDA and CRP, relative to groups 2 and 3." | 1.56 | Melatonin ameliorates some biochemical alterations following ketoconazole administration in rats. ( Abdul-Azeez, AR; Adeyemi, W; Alabi, Q; Okeleji, L; Olayaki, L; Omoniyi, J; Sampson, E; Shoyoye, A; Sulaiman, F, 2020) |
| "Ketoconazole is a first orally available anti-fungal drug which has been reported as a potent inhibitor of human cytochrome P-450." | 1.51 | Hepatoprotective effect of ketoconazole in chronic liver injury model. ( Ahmed, M; Akhtar, U; Ali, G; Shehzad, U; Tayyeb, A, 2019) |
| "The CCI-induced development of mechanical allodynia was attenuated by administration of either ketoconazole (10 nmol) or the p38 MAPK inhibitor, SB203580 (5 nmol)." | 1.51 | Inhibition of cytochrome P450c17 reduces spinal astrocyte activation in a mouse model of neuropathic pain via regulation of p38 MAPK phosphorylation. ( Beitz, AJ; Choi, SR; Lee, JH, 2019) |
| "Parkinson's disease is a growing threat to an ever-ageing population." | 1.46 | Validating the Predicted Effect of Astemizole and Ketoconazole Using a Drosophila Model of Parkinson's Disease. ( Styczyńska-Soczka, K; Zechini, L; Zografos, L, 2017) |
| "Invasion and metastasis are responsible for 90% of cancer-related mortality." | 1.42 | 4-Fluoro-3',4',5'-trimethoxychalcone as a new anti-invasive agent. From discovery to initial validation in an in vivo metastasis model. ( Bracke, ME; De Ryck, T; Katritzky, AR; Patronov, A; Roman, BI; Slavov, SH; Stevens, CV; Vanhoecke, BW, 2015) |
| " Specifically, a microbial natural product library was screened for hits that synergize the effect of a low dosage of ketoconazole (KTC) that alone shows little detectable fungicidal activity." | 1.34 | High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections. ( An, R; Bian, J; Chen, X; Chen, Z; Dai, H; Fu, C; Gao, H; Goodfellow, M; Huang, R; Jiang, Y; Kuai, J; Liu, J; Liu, Z; Min, F; Pei, G; Song, Y; Sun, H; Sun, N; Wang, J; Yan, K; Yang, K; You, J; Yu, Z; Zhang, L; Zhang, S; Zhang, X; Zhang, Y; Zhao, W; Zheng, C; Zhou, G; Zhuo, Y, 2007) |
| "Ketoconazole (KCZ) is an imidazole anti-fungal agent that is also effective in topical applications for treating seborrheic dermatitis and dandruff." | 1.33 | Topical application of ketoconazole stimulates hair growth in C3H/HeN mice. ( Jiang, J; Kojima, Y; Ogawa, H; Tsuboi, R, 2005) |
| " Structure-3A4 MDI relationship studies culminated in the discovery of a difluoro analogue, (S)-N-[1-(4-fluoro-3-morpholin-4-ylphenyl)ethyl]-3-(4-fluoro-phenyl)acrylamide (2), as an orally bioavailable KCNQ2 opener free of CYP3A4 MDI." | 1.32 | Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibiti ( Davis, CD; Dworetzky, S; Fitzpatrick, WC; Harden, D; He, H; Knox, RJ; Newton, AE; Philip, T; Polson, C; Sinz, MW; Sivarao, DV; Sun, LQ; Tertyshnikova, S; Weaver, D; Wu, YJ; Yeola, S; Zoeckler, M, 2003) |
| "Candida sepsis has become an increasing problem in ICU patients with up to 50 per cent mortality rate." | 1.28 | The use of ketoconazole in prophylaxis of Candida sepsis. ( Lloyd, L; Rietschel, P; VanEgmond, E, 1989) |
| "Pretreatment with ketoconazole for 48 hr completely abolished the protective effect of a subsequent therapy with amphotericin B, whether ketoconazole therapy was stopped (P less than ." | 1.27 | The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. ( Frick, PG; Schaffner, A, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (25.00) | 18.7374 |
| 1990's | 15 (25.00) | 18.2507 |
| 2000's | 10 (16.67) | 29.6817 |
| 2010's | 17 (28.33) | 24.3611 |
| 2020's | 3 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, YJ | 1 |
| Davis, CD | 1 |
| Dworetzky, S | 1 |
| Fitzpatrick, WC | 1 |
| Harden, D | 1 |
| He, H | 1 |
| Knox, RJ | 1 |
| Newton, AE | 1 |
| Philip, T | 1 |
| Polson, C | 1 |
| Sivarao, DV | 1 |
| Sun, LQ | 1 |
| Tertyshnikova, S | 1 |
| Weaver, D | 1 |
| Yeola, S | 1 |
| Zoeckler, M | 1 |
| Sinz, MW | 1 |
| Zhang, L | 1 |
| Yan, K | 1 |
| Zhang, Y | 1 |
| Huang, R | 1 |
| Bian, J | 1 |
| Zheng, C | 1 |
| Sun, H | 1 |
| Chen, Z | 1 |
| Sun, N | 1 |
| An, R | 1 |
| Min, F | 1 |
| Zhao, W | 1 |
| Zhuo, Y | 1 |
| You, J | 1 |
| Song, Y | 1 |
| Yu, Z | 1 |
| Liu, Z | 1 |
| Yang, K | 1 |
| Gao, H | 1 |
| Dai, H | 1 |
| Zhang, X | 1 |
| Wang, J | 1 |
| Fu, C | 1 |
| Pei, G | 1 |
| Liu, J | 2 |
| Zhang, S | 1 |
| Goodfellow, M | 1 |
| Jiang, Y | 1 |
| Kuai, J | 1 |
| Zhou, G | 1 |
| Chen, X | 1 |
| Park, JS | 1 |
| Yu, KA | 1 |
| Kang, TH | 1 |
| Kim, S | 1 |
| Suh, YG | 1 |
| Kamiński, K | 2 |
| Rapacz, A | 2 |
| Łuszczki, JJ | 2 |
| Latacz, G | 2 |
| Obniska, J | 1 |
| Kieć-Kononowicz, K | 2 |
| Filipek, B | 1 |
| Zagaja, M | 1 |
| Andres-Mach, M | 1 |
| Roman, BI | 1 |
| De Ryck, T | 1 |
| Patronov, A | 1 |
| Slavov, SH | 1 |
| Vanhoecke, BW | 1 |
| Katritzky, AR | 1 |
| Bracke, ME | 1 |
| Stevens, CV | 1 |
| O' Neill, PM | 1 |
| Stocks, PA | 1 |
| Sabbani, S | 1 |
| Roberts, NL | 1 |
| Amewu, RK | 1 |
| Shore, ER | 1 |
| Aljayyoussi, G | 1 |
| Angulo-Barturén, I | 1 |
| Belén, M | 1 |
| Bazaga, SF | 1 |
| Martínez, MS | 1 |
| Campo, B | 1 |
| Sharma, R | 1 |
| Charman, SA | 1 |
| Ryan, E | 1 |
| Chen, G | 1 |
| Shackleford, DM | 1 |
| Davies, J | 1 |
| Nixon, GL | 1 |
| Biagini, GA | 1 |
| Ward, SA | 1 |
| Koga, H | 1 |
| Munechika, Y | 1 |
| Matsumoto, H | 1 |
| Nanjoh, Y | 1 |
| Harada, K | 1 |
| Makimura, K | 1 |
| Tsuboi, R | 2 |
| Olayaki, L | 1 |
| Adeyemi, W | 1 |
| Alabi, Q | 1 |
| Okeleji, L | 1 |
| Shoyoye, A | 1 |
| Sampson, E | 1 |
| Sulaiman, F | 1 |
| Abdul-Azeez, AR | 1 |
| Omoniyi, J | 1 |
| Goto, A | 1 |
| Sakamoto, K | 1 |
| Hagiwara-Nagasawa, M | 1 |
| Kambayashi, R | 1 |
| Chiba, K | 1 |
| Nunoi, Y | 1 |
| Izumi-Nakaseko, H | 1 |
| Matsumoto, A | 1 |
| Sugiyama, A | 1 |
| Styczyńska-Soczka, K | 1 |
| Zechini, L | 1 |
| Zografos, L | 1 |
| Jiang, L | 1 |
| Pan, H | 1 |
| Agnihotri, S | 1 |
| Mansouri, S | 1 |
| Burrell, K | 1 |
| Li, M | 1 |
| Mamatjan, Y | 1 |
| Nejad, R | 1 |
| Kumar, S | 1 |
| Jalali, S | 1 |
| Singh, SK | 1 |
| Vartanian, A | 1 |
| Chen, EX | 1 |
| Karimi, S | 1 |
| Singh, O | 1 |
| Bunda, S | 1 |
| Mansouri, A | 1 |
| Aldape, KD | 1 |
| Zadeh, G | 1 |
| Choi, SR | 2 |
| Roh, DH | 1 |
| Yoon, SY | 1 |
| Choi, HS | 1 |
| Kang, SY | 1 |
| Han, HJ | 1 |
| Beitz, AJ | 2 |
| Lee, JH | 2 |
| Amra, K | 1 |
| Momin, M | 1 |
| Yang, F | 1 |
| Takeuchi, T | 1 |
| Tsuneyama, K | 1 |
| Yokoi, T | 1 |
| Oda, S | 1 |
| Akhtar, U | 1 |
| Ahmed, M | 1 |
| Tayyeb, A | 1 |
| Shehzad, U | 1 |
| Ali, G | 1 |
| Seif El-Din, SH | 1 |
| Abdel-Aal Sabra, AN | 1 |
| Hammam, OA | 1 |
| El-Lakkany, NM | 1 |
| Kaur, P | 1 |
| Sodhi, RK | 1 |
| Davis, JP | 1 |
| Salmon, M | 1 |
| Pope, NH | 1 |
| Lu, G | 1 |
| Su, G | 1 |
| Meher, A | 1 |
| Ailawadi, G | 1 |
| Upchurch, GR | 1 |
| Zhang, H | 1 |
| Wang, K | 1 |
| Zhang, G | 1 |
| Ho, HI | 1 |
| Gao, A | 1 |
| Shakya, N | 1 |
| Sane, SA | 1 |
| Vishwakarma, P | 1 |
| Bajpai, P | 1 |
| Gupta, S | 1 |
| Kamberi, P | 1 |
| Sobel, RA | 1 |
| Clemons, KV | 2 |
| Stevens, DA | 3 |
| Pappagianis, D | 1 |
| Williams, PL | 1 |
| Goswick, SM | 1 |
| Brenner, GM | 1 |
| Jiang, J | 1 |
| Kojima, Y | 1 |
| Ogawa, H | 1 |
| Schiaffella, F | 1 |
| Macchiarulo, A | 1 |
| Milanese, L | 1 |
| Vecchiarelli, A | 1 |
| Fringuelli, R | 1 |
| Hoyos, GL | 1 |
| McEwen, JG | 1 |
| Brummer, E | 1 |
| Castañeda, E | 1 |
| Restrepo, A | 1 |
| Jones, DB | 1 |
| Valiant, ME | 1 |
| Frost, BM | 1 |
| Maldonado, RA | 1 |
| Molina, J | 1 |
| Payares, G | 1 |
| Urbina, JA | 1 |
| Flattery, AM | 1 |
| Abruzzo, GK | 1 |
| Gill, CJ | 1 |
| Smith, JG | 1 |
| Bartizal, K | 1 |
| Gras, J | 1 |
| Llenas, J | 2 |
| Palacios, JM | 1 |
| Roberts, DJ | 2 |
| Hey, JA | 1 |
| del Prado, M | 1 |
| Sherwood, J | 1 |
| Kreutner, W | 1 |
| Egan, RW | 1 |
| Kinnamon, KE | 1 |
| Poon, BT | 1 |
| Hanson, WL | 1 |
| Waits, VB | 1 |
| Cohen, H | 1 |
| Benjamin, J | 1 |
| Kaplan, Z | 1 |
| Kotler, M | 1 |
| Sano, N | 1 |
| Nio, M | 1 |
| Ishii, T | 1 |
| Amae, S | 1 |
| Wada, M | 1 |
| Nishi, K | 1 |
| Endo, N | 1 |
| Hayashi, Y | 1 |
| Ohi, R | 1 |
| O'Day, DM | 1 |
| Head, WS | 1 |
| Robinson, RD | 1 |
| Williams, TE | 1 |
| Gedde, S | 1 |
| Schmitt, HJ | 1 |
| Edwards, F | 1 |
| Andrade, J | 1 |
| Niki, Y | 1 |
| Armstrong, D | 1 |
| Bava, AJ | 1 |
| Negroni, R | 1 |
| Georgiev, VS | 1 |
| Van Cutsem, J | 4 |
| Singh, SM | 2 |
| Sharma, S | 2 |
| Chatterjee, PK | 2 |
| Van Gerven, F | 1 |
| Fransen, J | 1 |
| Schrooten, P | 1 |
| Janssen, PA | 1 |
| Hector, RF | 1 |
| Yee, E | 1 |
| Defaveri, J | 1 |
| Graybill, JR | 1 |
| Khan, R | 1 |
| Rietschel, P | 1 |
| VanEgmond, E | 1 |
| Lloyd, L | 1 |
| Nobre, G | 1 |
| Mendes, E | 1 |
| Charrua, MJ | 1 |
| Cruz, O | 1 |
| Ackerbauer, H | 1 |
| Meingassner, JG | 2 |
| Mieth, H | 1 |
| Smith, KJ | 1 |
| Warnock, DW | 1 |
| Kennedy, CT | 1 |
| Johnson, EM | 1 |
| Hopwood, V | 1 |
| Vanden Bossche, H | 1 |
| Schaude, M | 1 |
| Palmer, GC | 1 |
| Ordy, JM | 1 |
| Simmons, RD | 1 |
| Strand, JC | 1 |
| Mullen, GB | 1 |
| Kinsolving, CR | 1 |
| St Georgiev, V | 1 |
| Allen, SD | 1 |
| Whiting, PH | 1 |
| Thomson, AW | 1 |
| Simpson, JG | 1 |
| Ahmad, S | 1 |
| Boone, D | 1 |
| Hall, D | 1 |
| Cole, JJ | 1 |
| Dennis, MB | 1 |
| Schaffner, A | 1 |
| Frick, PG | 1 |
| Sobel, JD | 1 |
| Muller, G | 1 |
| McCormick, JF | 1 |
4 reviews available for ketoconazole and Disease Models, Animal
| Article | Year |
|---|---|
Azole therapy of clinical and experimental coccidioidomycosis.
Topics: Administration, Oral; Animals; Antifungal Agents; Azoles; Coccidioidomycosis; Disease Models, Animal | 2007 |
Treatment and developmental therapeutics in aspergillosis. 2. Azoles and other antifungal drugs.
Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillosis, Allergic Bronchopulmonary; Azoles; Clotrim | 1992 |
Oral and parenteral treatment with itraconazole in various superficial and systemic experimental fungal infections. Comparisons with other antifungals and combination therapy.
Topics: Animals; Antifungal Agents; Disease Models, Animal; Itraconazole; Ketoconazole; Mycoses | 1990 |
Cyclosporine: toxicity, metabolism, and drug interactions--implications from animal studies.
Topics: Animals; Cyclosporins; Disease Models, Animal; Dogs; Drug Interactions; Gentamicins; Humans; Ketocon | 1985 |
56 other studies available for ketoconazole and Disease Models, Animal
| Article | Year |
|---|---|
Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibiti
Topics: Administration, Oral; Animals; Biological Availability; Cell Line; Cinnamates; Cytochrome P-450 CYP3 | 2003 |
High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections.
Topics: Algorithms; Animals; Antifungal Agents; Cell Line; Depsipeptides; Disease Models, Animal; Drug Combi | 2007 |
Discovery of novel indazole-linked triazoles as antifungal agents.
Topics: Administration, Oral; Animals; Antifungal Agents; Aspergillus; Candida; Disease Models, Animal; Inda | 2007 |
Design, synthesis and biological evaluation of new hybrid anticonvulsants derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide derivatives.
Topics: Amides; Animals; Anticonvulsants; Benzylamines; Convulsants; Disease Models, Animal; Dose-Response R | 2015 |
Design, synthesis, and anticonvulsant activity of new hybrid compounds derived from 2-(2,5-dioxopyrrolidin-1-yl)propanamides and 2-(2,5-dioxopyrrolidin-1-yl)butanamides.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Ele | 2015 |
4-Fluoro-3',4',5'-trimethoxychalcone as a new anti-invasive agent. From discovery to initial validation in an in vivo metastasis model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Products; Cell Line, Tumor; Cell Movement; Ce | 2015 |
Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria.
Topics: Administration, Oral; Animals; Antimalarials; Disease Models, Animal; Drug Stability; Humans; Inhibi | 2018 |
Guinea pig seborrheic dermatitis model of Malassezia restricta and the utility of luliconazole.
Topics: Administration, Topical; Animals; Antifungal Agents; Dermatitis, Seborrheic; Disease Models, Animal; | 2020 |
Melatonin ameliorates some biochemical alterations following ketoconazole administration in rats.
Topics: Animals; Antifungal Agents; Central Nervous System Depressants; Disease Models, Animal; Follicle Sti | 2020 |
Utilization of the chronic atrioventricular block cynomolgus monkey as an in vivo model to evaluate drug interaction-associated torsade de pointes.
Topics: Animals; Atrioventricular Block; Chronic Disease; Disease Models, Animal; Drug Synergism; Ketoconazo | 2020 |
Validating the Predicted Effect of Astemizole and Ketoconazole Using a Drosophila Model of Parkinson's Disease.
Topics: Animals; Astemizole; Disease Models, Animal; Dose-Response Relationship, Drug; Drosophila; Drug Repo | 2017 |
Functions of CaPhm7 in the regulation of ion homeostasis, drug tolerance, filamentation and virulence in Candida albicans.
Topics: Animals; Candida albicans; Candidiasis; Disease Models, Animal; Drug Resistance, Fungal; Fungal Prot | 2018 |
Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-R | 2019 |
Spinal cytochrome P450c17 plays a key role in the development of neuropathic mechanical allodynia: Involvement of astrocyte sigma-1 receptors.
Topics: 3-Hydroxysteroid Dehydrogenases; Animals; Astrocytes; Dihydrotestosterone; Disease Models, Animal; H | 2019 |
Formulation evaluation of ketoconazole microemulsion-loaded hydrogel with nigella oil as a penetration enhancer.
Topics: Administration, Topical; Animals; Antifungal Agents; Aspergillus niger; Candida albicans; Delayed-Ac | 2019 |
Experimental Evidence of Liver Injury by BSEP-Inhibiting Drugs With a Bile Salt Supplementation in Rats.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; Chemical and Drug Induced Liver I | 2019 |
Hepatoprotective effect of ketoconazole in chronic liver injury model.
Topics: Actins; Animals; Carbon Tetrachloride; Cell Death; Chemical and Drug Induced Liver Injury; Disease M | 2019 |
Inhibition of cytochrome P450c17 reduces spinal astrocyte activation in a mouse model of neuropathic pain via regulation of p38 MAPK phosphorylation.
Topics: Animals; Astrocytes; Constriction, Pathologic; Disease Models, Animal; Hyperalgesia; Imidazoles; Ket | 2019 |
Effect of ketoconazole, a cytochrome P450 inhibitor, on the efficacy of quinine and halofantrine against Schistosoma mansoni in mice.
Topics: Animals; Anthelmintics; Disease Models, Animal; Drug Synergism; Female; Humans; Intestines; Ketocona | 2013 |
Memory recuperative potential of rifampicin in aluminum chloride-induced dementia: role of pregnane X receptors.
Topics: Acetylcholinesterase; Aluminum Chloride; Aluminum Compounds; Amyloid; Animals; Brain; Chlorides; Cog | 2015 |
Pharmacologic blockade and genetic deletion of androgen receptor attenuates aortic aneurysm formation.
Topics: Androgen Antagonists; Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Cytokines; Disease Mode | 2016 |
Synergistic anti-candidal activity of tetrandrine on ketoconazole: an experimental study.
Topics: Animals; Antifungal Agents; Benzylisoquinolines; Candida albicans; Candidiasis, Vulvovaginal; Colony | 2010 |
Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.
Topics: Animals; Antiprotozoal Agents; Cinnamates; Cricetinae; Disease Models, Animal; Drug Therapy, Combina | 2011 |
A murine model of coccidioidal meningitis.
Topics: Animals; Antifungal Agents; Coccidioides; Coccidioidomycosis; Crosses, Genetic; Disease Models, Anim | 2003 |
Activities of therapeutic agents against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis.
Topics: Acetamides; Adolescent; Amebiasis; Amebicides; Amphotericin B; Animals; Central Nervous System Proto | 2003 |
Topical application of ketoconazole stimulates hair growth in C3H/HeN mice.
Topics: Administration, Cutaneous; Alopecia; Animals; Antifungal Agents; Disease Models, Animal; Drug Admini | 2005 |
Novel ketoconazole analogues based on the replacement of 2,4-dichlorophenyl group with 1,4-benzothiazine moiety: design, synthesis, and microbiological evaluation.
Topics: Animals; Candida albicans; Candidiasis; Crystallography, X-Ray; Cytochrome P-450 Enzyme Inhibitors; | 2006 |
Chronic murine paracoccidioidomycosis: effect of ketoconazole on clearance of Paracoccidioides brasiliensis and immune response.
Topics: Animals; Antibodies, Fungal; Chronic Disease; Disease Models, Animal; Fungi; Hypersensitivity, Delay | 1984 |
Chemotherapy of experimental endogenous Candida albicans endophthalmitis.
Topics: Amphotericin B; Animals; Antifungal Agents; Candidiasis; Disease Models, Animal; Drug Therapy, Combi | 1980 |
An experimental model for evaluation of antifungal agents in a Trichophyton mentagrophytes infection of guinea pigs.
Topics: Animals; Antifungal Agents; Clotrimazole; Disease Models, Animal; Female; Griseofulvin; Guinea Pigs; | 1984 |
Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas' disease.
Topics: Animals; Antifungal Agents; Chagas Disease; Disease Models, Animal; Ergosterol; Female; Ketoconazole | 1993 |
New model of oropharyngeal and gastrointestinal colonization by Candida albicans in CD4+ T-cell-deficient mice for evaluation of antifungal agents.
Topics: Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Antifungal Agents; Candida albicans; CD4-Pos | 1996 |
The role of ketoconazole in the QTc interval prolonging effects of H1-antihistamines in a guinea-pig model of arrhythmogenicity.
Topics: Animals; Antifungal Agents; Arrhythmias, Cardiac; Disease Models, Animal; Dose-Response Relationship | 1996 |
Some observations on the cardiotoxic and drug interaction profiles of second generation antihistamines as measured in the guinea pig.
Topics: Animals; Antifungal Agents; Butyrophenones; Disease Models, Animal; Drug Interactions; Electrocardio | 1996 |
The guinea pig model for assessing cardiotoxic proclivities of second generation antihistamines.
Topics: Animals; Antifungal Agents; Butyrophenones; Cats; Disease Models, Animal; Drug Interactions; Guinea | 1996 |
In pursuit of drugs for American trypanosomiasis: evaluation of some "standards" in a mouse model.
Topics: Animals; Antiprotozoal Agents; Chagas Disease; Disease Models, Animal; Female; Imipramine; Ketoconaz | 1997 |
Administration of high-dose ketoconazole, an inhibitor of steroid synthesis, prevents posttraumatic anxiety in an animal model.
Topics: Animals; Anxiety; Body Weight; Disease Models, Animal; Endocrine Glands; Ketoconazole; Male; Psychom | 2000 |
Oral FK 506 blood levels are elevated in pig short bowel model: further investigations with co-administration of an intestinal CYP3A4 inhibitor.
Topics: Administration, Oral; Anastomosis, Surgical; Animals; Area Under Curve; Cytochrome P-450 CYP3A; Cyto | 2002 |
The evaluation of therapeutic responses in experimental keratomycosis.
Topics: Administration, Oral; Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Colony Count | 1992 |
Comparison of azoles against aspergilli in vitro and in an experimental model of pulmonary aspergillosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Aspergillosis, Allergic Bronchopulmonary; | 1992 |
Comparative study of six antifungal treatments in an experimental model of murine cryptococcosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Disease Models, | 1992 |
Clinical and experimental mycotic keratitis caused by Aspergillus terreus and the effect of subconjunctival oxiconazole treatment in the animal model.
Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Aspergillus; Corneal Ulcer; Disease Model | 1990 |
The in vitro antifungal activity of ketoconazole, zinc pyrithione, and selenium sulfide against Pityrosporum and their efficacy as a shampoo in the treatment of experimental pityrosporosis in guinea pigs.
Topics: Animals; Antifungal Agents; Dermatitis, Seborrheic; Dermatomycoses; Disease Models, Animal; Guinea P | 1990 |
Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis.
Topics: Administration, Oral; Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Crypto | 1990 |
Treatment of chronic murine chromoblastomycosis with the triazole SCH39304.
Topics: Animals; Antifungal Agents; Chromoblastomycosis; Chronic Disease; Disease Models, Animal; Female; It | 1990 |
Oral, topical and parenteral antifungal treatment with itraconazole in normal and in immunocompromised animals.
Topics: Administration, Oral; Administration, Topical; Animals; Antifungal Agents; Disease Models, Animal; F | 1989 |
Clinical and experimental mycotic corneal ulcer caused by Aspergillus fumigatus and the effect of oral ketoconazole in the treatment.
Topics: Administration, Oral; Animals; Aspergillosis; Aspergillus fumigatus; Child; Corneal Ulcer; Disease M | 1989 |
The use of ketoconazole in prophylaxis of Candida sepsis.
Topics: Animals; Candidiasis; Disease Models, Animal; Guinea Pigs; Hydrogen-Ion Concentration; Ketoconazole; | 1989 |
Ketoconazole resistance in Torulopsis glabrata.
Topics: Animals; Candida; Candidiasis; Disease Models, Animal; Drug Resistance, Microbial; Humans; Immunosup | 1989 |
[Experimental renal infection with Aspergillus fumigatus in mice: a chemotherapeutic model of an organic mycosis].
Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Disease Models, An | 1985 |
Azole resistance in Candida albicans.
Topics: Adult; Animals; Antifungal Agents; Candida albicans; Candidiasis; Candidiasis, Chronic Mucocutaneous | 1986 |
A diffusion chamber technique for testing of antifungal drugs against Sporothrix schenckii in vivo.
Topics: Amphotericin B; Animals; Antifungal Agents; Disease Models, Animal; Female; Itraconazole; Ketoconazo | 1986 |
Comparisons of ketoconazole, PR 969-566, PR 967-234, and PR 967-248 as antifungals in vitro and in the rat model of candidal vaginitis based on efficacy/safety profiles.
Topics: Animals; Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Disease Models, Animal; Female; Fung | 1988 |
An animal model for fungal peritonitis: evaluation of therapeutic options.
Topics: Administration, Oral; Animals; Candidiasis; Catheters, Indwelling; Disease Models, Animal; Drug Eval | 1986 |
The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis.
Topics: Amphotericin B; Animals; Aspergillosis; Disease Models, Animal; Female; Humans; In Vitro Techniques; | 1985 |
Experimental chronic vaginal candidosis in rats.
Topics: Animals; Candidiasis, Vulvovaginal; Disease Models, Animal; Female; Ketoconazole; Rats; Rats, Inbred | 1985 |